CTLA4 and melanoma: The superiority of checkpoint blockade with anti-CTLA-4 or anti-PD-1 mAbs to chemotherapy in the treatment of stage IV (metastatic) melanoma, has been proven in multiple randomized clinical trials (excellently reviewed in [24]).